Principal component analysis in COVID-19 clinical variable clustering in Santiago de Cuba
Keywords:
COVID-19, symptoms, personal pathological history, analysis of principal componentsAbstract
Introduction: Since March 2020, Cuba has been affected by SARS-CoV-2, a highly infectious coronavirus that causes COVID-19. In COVID-19 a set of associated symptoms is presented and its evolution can be influenced by the presence of certain personal pathological antecedents in the host.
Objective: To identify through principal components the grouping of clinical variables in cases with COVID-19 in Santiago de Cuba province, Cuba.
Methods: We conducted an observational, descriptive and transversal study. The study population consisted of the 49 confirmed cases with COVID-19 in the province of Santiago de Cuba. Ten clinical variables were selected: nine related to symptoms and personal pathological history, and one to the state “deceased”. Principal component analysis was applied as a statistical technique.
Results: Variables were represented at the level of the first two principal components. The first component was associated to symptoms and the second component to personal pathological antecedents not associated to the respiratory system. This representation revealed that variables leading to an unfavorable evolution of cases were located in the first and fourth quadrants of the plane, being remarkable for those located in the fourth quadrant. The second and third quadrants were indicators of the favorable evolution, being marked in the second quadrant.
Conclusions: The principal component analysis groups the clinical variables and corroborates that personal pathological antecedents have an essential role in the unfavorable evolution of patients with COVID-19.
Downloads
References
1. WHO. Coronavirus Disease (COVID-19) Dashboard. 2020. [actualizado: 15/06/2020; acceso: 01/06/2020]. Disponible en: https://covid19.who.int/
2. Dashboard Cuba: Covid19. 2020. [actualizado: 15/06/2020; acceso: 10/06/2020]. Disponible en: https://covid19cubadata.github.io/#cuba
3. Wolfgang K, Léopold S. Applied Multivariate Statistical Analysis. Fourth Edition. Berlin: Springer-Verlag Heidelberg; 2015.
4. World Medical Association. Declaration of Helsinki: Ethical principles for medical research involving human subjects. Journal of American Medical Association. 2013;310(20):2191-4.
5. OMS. Preguntas y respuestas sobre la enfermedad por coronavirus (COVID-19). 2020. [actualizado: 15/06/2020; 10/06/2020]. Disponible en: https://www.who.int/es/emergencies/diseases/novel-coronavirus-2019/advice-for-public/q-a-coronaviruses#:~:text=sintomas
6. Candelaria Brito JC, Díaz Cruz SA, Acosta Pérez DM, Junco Sena B, Rodríguez Méndez A. Primera comunidad en cuarentena por la COVID-19 de Cuba. Rev Ciencias Médicas de Pinar del Río. 2020 [acceso: 10/06/2020]; 24(3):4485. Disponible en: http://revcmpinar.sld.cu/index.php/publicaciones/article/view/4485
7. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. 2019. The Lancet. 2020;395(10223):497-506.
8. Xie J, Tong Z, Guan X, Du B, Qiu H. Clinical characteristics of patients who died of coronavirus disease 2019 in China. Journal of American Medical Association Network Open. 2020 [acceso: 10/06/2020]; 3(4):e205619. Disponible en: https://jamanetwork.com/journals/jamane-tworkopen/fullarticle/2764293
9. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ Military Health. 2020 [acceso: 10/06/2020]; 3(4):e205619. Disponible en: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2764293#editorial-comment-tab
10. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. 2020;395:1054-62.
11. Bos JM, Hebl VB, Oberg AL, Sun Z, Herman DS, Teekakirikul P, et al. Marked Up-Regulation of ACE2 in Hearts of Patients with Obstructive Hypertrophic Cardiomyopathy: Implications for SARS-CoV-2-Mediated COVID-19. Mayo Clinic Proceeding. 2020:1-15. DOI: 10.1016/j.mayocp.2020.04.028
12. Ruocco G, Feola M, Palazzuoli A. Hypertension prevalence in human coronavirus disease: the role of ACE system in infection spread and severity. International Journal of Infectious Diseases. 2020;95:373-5. DOI: 10.1016/j.ijid.2020.04.058
13. Cuba. Ministerio de Salud Pública, Dirección de Registros Médicos y Estadísticas de Salud. Anuario de Salud 2019. La Habana; 2020. [acceso: 10/06/2020]. p. 97. Disponible en: https://salud.msp.gob.cu/?tag=anuario-estadistico-de-salud
14. Rodríguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, Villamizar-Peña R, Holguín-Rivera Y, Escalera-Antezana JP, et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Medicine and Infectious Disease. 2020;34:101623. DOI: 10.1016/j.tmaid.2020.101623
15. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS. Journal of Virology. 2020;94(7):e00127. DOI: 10.1128/JVI.00127-20
16. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? The Lancet. Respiratory Medicine. 2020;8(4):e21. DOI: 10.1016/S2213-2600(20)30116-8
17. Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Eurosurveillance. 2020;25(10):2000180. DOI: 10.2807/1560-7917.ES.2020.25.10.2000180
18. Liu Y, Funk S, Flashe S. The contribution of pre-symptomatic transmission to the COVID-19 outbreak. Centre for Mathematical Modelling of Infectious Diseases. 2020;5:58. DOI: 10.12688/wellcomeopenres.15788.1
19. Rodríguez Labrada R, Vazquez-Mojena Y, Velázquez-Pérez L. Transmisión asintomática y presintomática del SARS-CoV2: la cara oculta de la COVID-19. Anales de la Academia de Ciencias de Cuba. 2020 [acceso: 10/06/2020]; 10(2). Disponible en: http://www.revistaccuba.cu/index.php/revacc/article/view/770/807
Downloads
Published
How to Cite
Issue
Section
License
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes: Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons (CC-BY-NC 4.0) que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista. Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista. Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).
Como Revista Cubana de Investigaciones Biomédicas forma parte de la red SciELO, una vez los artículos sean aceptados para entrar al proceso editorial (revisión), estos pueden ser depositados por parte de los autores, si estan de acuerdo, en SciELO preprints, siendo actualizados por los autores al concluir el proceso de revisión y las pruebas de maquetación.
